Recombinant SCF, marketed as Ancestim, in combination with G-CSF allowed successful collection of CD34+ progenitors in the peripheral blood of poorly mobilizing cancer patients (Lapierre et al., 2011). This evidence concerns the gene CSF3 and cancer.